Natera Legal Officer Sells $8.45 Million in Company Shares
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
naterainsider-trading
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Daniel Rabinowitz, Chief Legal Officer of Natera Inc. (NTRA), sold shares worth approximately $8.45 million on June 27, 2026. The transaction, disclosed in a regulatory filing with the Securities and Exchange Commission, involved the sale of 118,000 common shares at an average price of $71.61 per share. This sale represents one of the largest single-disposal events by a Natera insider over the past two years and occurred as the company’s stock trades near its 52-week high.
Insider sales are a routine aspect of executive compensation, but the magnitude and timing of this transaction warrant scrutiny. The last comparable sale by a C-suite executive at Natera occurred on August 15, 2025, when the Chief Commercial Officer sold just over $2.1 million in stock following a strong quarterly earnings report. The current macro backdrop for growth-oriented healthcare stocks remains challenging, with the iShares Biotechnology ETF (IBB) down 4% year-to-date as of late June 2026, pressured by higher discount rates and regulatory uncertainty.
What triggered this specific event is the impending regulatory catalyst for Natera’s Signatera test. The U.S. Food and Drug Administration is reviewing Signatera’s pre-market approval application for use in colorectal cancer, with a decision expected by the third quarter of 2026. This review is a binary event for the company’s commercial strategy. Large, pre-catalyst insider sales can signal a reassessment of near-term risk or a desire to lock in gains ahead of potential volatility, shifting investor perception from routine portfolio management to a more tactical move.
The sale reduced Rabinowitz’s direct holdings by roughly 40%, leaving him with approximately 177,000 shares. Natera’s stock closed at $72.10 on the day of the filing, just 0.7% above the reported average sale price. The company’s market capitalization stands at $8.7 billion. Year-to-date, NTRA shares have gained 22%, significantly outperforming the broader SPDR S&P Biotech ETF (XBI), which is flat for the period.
A comparison of insider activity over the past 12 months shows a net selling trend. While there have been periodic option exercises and subsequent sales, the aggregate dollar value of sales by all insiders exceeds purchases by a ratio of more than 15-to-1. The table below illustrates the scale of Rabinowitz’s transaction against recent peer activity in the genomic testing sector:
| Company (Ticker) | Insider Position | Date | Sale Value | % of Holding Sold |
|---|---|---|---|---|
| Natera (NTRA) | Chief Legal Officer | Jun 27, 2026 | $8.45M | ~40% |
| Guardant Health (GH) | Chief Medical Officer | May 5, 2026 | $1.2M | ~12% |
| Invitae (NVTA) | Former CEO | Feb 14, 2026 | $0.3M | ~95% |
The sale creates a direct headwind for Natera’s stock price in the near term, adding technical supply and potentially dampening sentiment ahead of the FDA decision. It may benefit competing liquid biopsy firms like Guardant Health (GH) and Exact Sciences (EXAS) by diverting cautious capital towards peers with less pronounced insider selling pressure. A conservative estimate suggests a 3-5% relative underperformance for NTRA versus this peer group over the next month, all else being equal, as the market prices in increased uncertainty.
A key limitation to this analysis is that the sale could be part of a long-planned 10b5-1 trading plan, established months prior to shield the executive from accusations of trading on material non-public information. Without confirmation of such a plan, the market must weigh the transaction’s optics. The immediate flow of funds is likely moving out of single-stock NTRA positions and into broader sector ETFs or cash, as evidenced by elevated short interest, which has crept up to 8% of the float.
Investors should monitor two specific catalysts with defined timelines. The primary event is the FDA’s decision on Signatera for colorectal cancer, due by the end of Q3 2026. Secondary is Natera’s Q2 2026 earnings report, scheduled for late July, which will provide an update on test volumes and cash burn. Key technical levels for the stock include immediate support at the 50-day moving average near $68.50 and resistance at the 52-week high of $75.20.
If the FDA decision is positive, the recent selling pressure will likely be overshadowed by fundamental momentum. A negative or delayed decision, however, could validate the cautious signal sent by the insider sale and trigger a steeper correction. Market participants are also watching the 10-year Treasury yield, currently at 4.2%, as a higher rate environment continues to pressure valuations for pre-profitability healthcare names.
A 10b5-1 plan is a pre-arranged, automated trading plan established by corporate insiders to buy or sell shares at predetermined times or prices. It provides an affirmative defense against allegations of insider trading by demonstrating the trades were scheduled before the insider possessed material non-public information. The existence of such a plan for Daniel Rabinowitz’s sale has not been publicly confirmed in the initial filing, which is a detail often clarified in subsequent amendments.
Natera CEO Steve Chapman has a different trading pattern, characterized by smaller, more frequent sales often following option exercises. Over the past 18 months, Chapman’s single-sale transactions have typically been under $2 million in value. In contrast, Rabinowitz’s $8.45 million sale is notable for its size relative to his remaining holdings, suggesting a more significant reduction in personal exposure to the company’s stock price ahead of a known catalyst.
Historically, large insider sales at Natera have preceded periods of consolidation or mild underperformance. For example, following a cluster of sales totaling over $15 million by multiple executives in November 2024, the stock traded sideways for the subsequent six weeks despite a rising broader market. The stock’s long-term trajectory, however, has remained driven by fundamental execution on test volumes and reimbursement wins, indicating that insider sales are a secondary sentiment indicator rather than a primary price driver.
The $8.45 million sale signals elevated caution by a key insider ahead of a pivotal FDA decision for Natera’s core product.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Trade 800+ global stocks & ETFs
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.